Abstract
Introduction:
The use of health technology assessment (HTA) is growing steadily in Europe,
and the U.S. government has recently announced $1.1 billion in funding for
comparative effectiveness research (CER) as part of its planned overhaul of
the U.S. healthcare system. Payers in all markets will increasingly compare
new drugs with established therapies and offer the most favorable pricing and
reimbursement terms only to drugs that are deemed innovative.
Questions Answered in This Report:
- HTA has become a major focus of attention in healthcare systems around the
world in recent years. What are the key elements of HTA? What approaches
have the authorities in leading pharmaceutical markets taken to the use of
HTA?
- European governments have used various forms of HTA for many years. How
do HTA strategies vary from one European country to another? What common
trends can be observed in Europe?
- The United States has been much slower than other mature pharmaceutical
markets to embrace HTA. Which U.S. organizations have practiced HTA in the
past? What action has the U.S. government recently taken to stimulate greater
use of CER in the United States?
Scope:
- Increasing focus on HTA: defi nitions of HTA; role of health
economic evaluation; strategies in major markets.
- Use of HTA in leading markets: France; Germany; Italy; Spain;
United Kingdom; United States; international collaborations.
- Outlook and implications for the pharmaceutical industry: European
industry' s key principles for HTA; challenges presented by the adoption of CER
in the United States; key message to payers.
| 
View Cart
